The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic testing and treatment patterns in Black patients (pts) with chronic lymphocytic leukemia (CLL) from the informCLL prospective, observational registry.
 
Jacqueline Claudia Barrientos
Honoraria - Janssen
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Genentech; Gilead Sciences; Innate Pharma; Pharmacyclics
Research Funding - AstraZeneca (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst)
 
Anthony Mato
Consulting or Advisory Role - Abbvie/Genentech; Acerta Pharma/AstraZeneca; Adaptive Biotechnologies; Bristol-Myers Squibb/Pfizer; Celgene; Curio/Vaniam Group; DTRM; Johnson & Johnson; Loxo/Lilly; Merck; Pharmacyclics; TG Therapeutics; Verastem
Research Funding - Abbvie/Genentech; Acerta Pharma/AstraZeneca; Adaptive Biotechnologies; DTRM; Genmab; Johnson & Johnson; LOXO; Nurix; Pharmacyclics; Regeneron; Sunesis Pharmaceuticals; TG Therapeutics
 
Jeff Porter Sharman
Employment - US Oncology Network
Consulting or Advisory Role - Abbvie; Acerta Pharma/AstraZeneca; Beigene; Beigene; Bristol-Myers Squibb; Genentech; Merck; TG Therapeutics
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Danielle M. Brander
Honoraria - Genentech; TG Therapeutics; Verastem
Consulting or Advisory Role - Abbvie; Genentech/Abbvie; Novartis; Pfizer; Pharmacyclics; TG Therapeutics
Research Funding - Abbvie (Inst); ArQule (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); DTRM (Inst); Genentech (Inst); LOXO (Inst); MEI Pharma (Inst); Novartis (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; Teva; TG Therapeutics
Other Relationship - Novartis
 
Meghan E. Gutierrez
No Relationships to Disclose
 
Linda Wu
Employment - Janssen
Stock and Other Ownership Interests - Jana Analysis
Patents, Royalties, Other Intellectual Property - Jana Analysis
 
Sumeet Panjabi
Employment - Janssen
Stock and Other Ownership Interests - Amgen; Janssen
Travel, Accommodations, Expenses - Amgen; Janssen
 
Alex Young
Employment - Pharmacyclics
Stock and Other Ownership Interests - Pharmacyclics
 
Sandhya Upasani
Employment - Biomea Fusion (I); Pharmacyclics; Protagonist Therapeutics (I)
Stock and Other Ownership Interests - Biomea Fusion (I); Pharmaca; Protagonist Therapeutics (I)
Patents, Royalties, Other Intellectual Property - Biomea Fusion (I)
 
Maoko Naganuma
Employment - Pharmacyclics
Stock and Other Ownership Interests - Abbvie
 
Nilanjan Ghosh
Consulting or Advisory Role - Adaptive Biotechnologies; AstraZeneca; Beigene; Bristol-Myers Squibb; Genmab; Gilead Sciences; Incyte; Karyopharm Therapeutics; Loxo/Lilly; Novartis; Pharmacyclics/Janssen; Roche/Genentech; Seagen; TG Therapeutics
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Epizyme; Kite/Gilead; Pharmacyclics/Janssen
Research Funding - Abbvie (Inst); Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Morphosys (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)